Tag

Kras

All articles tagged with #kras

health21 days ago•6 min saved

KRAS-targeting pancreatic cancer drug daraxonrasib could redefine treatment

A new pancreatic cancer drug, daraxonrasib, paired with chemotherapy, nearly doubles survival in advanced disease. In Phase 3, overall survival was 13.2 months with the combo vs 6.7 months with chemo alone, and earlier data showed progression-free survival around 8 months at the highest dose. The FDA has fast-tracked the drug and allowed expanded access, with potential use beyond KRAS-mutant tumors and possible earlier-line therapy consideration.

via NBC News|

#clinical-trials #daraxonrasib #health

health1 month ago•3 min saved

KRAS-targeted therapy extends life in pancreatic cancer, signaling a new era

A pancreatic cancer patient on Revolution Medicines' KRAS inhibitor daraxonrasib reports a dramatic extension of life, illustrating how targeting historically 'undruggable' KRAS can yield durable benefits and fueling optimism for KRAS inhibitors across pancreatic and other KRAS-mutant cancers.

via statnews.com|

#clinical-trials #health #kras

science2 months ago•8 min saved

Triple-Drug KRAS Attack Erases Pancreatic Tumors in Mice

CNIO researchers report a triple-drug regimen that blocks the KRAS signaling pathway at three points—using daraxonrasib, afatinib, and SD36—to induce durable tumor regression and prevent resistance in three mouse models of pancreatic ductal adenocarcinoma (PDAC) with minimal toxicity. While promising, they caution that the approach is not yet ready for clinical trials and would require further development to adapt for human use, per the PNAS study.

via SciTechDaily|

#cnio #combination-therapy #drug-resistance

health2 months ago•5 min saved

KRAS-ERK switch could revive chemotherapy response in pancreatic cancer

Researchers identify a KRAS/ERK/JUNB signaling axis that suppresses the differentiation regulator GATA6, pushing pancreatic tumors from a classical, chemo‑sensitive state to a basal, chemo‑resistant one; inhibiting this pathway raises GATA6 levels, reverting cells to a more treatable state and enhancing the effectiveness of standard chemotherapy when paired with targeted therapies.

via SciTechDaily|

#chemotherapy-resistance #erk #gata6

science3 months ago•22 min saved

Medico’s Mouse‑Only “Cure” Sparks Hype and Scrutiny Over Pancreatic Cancer Trial

Spanish biochemist Mariano Barbacid announced a “cure” for pancreatic cancer based on a triple‑drug therapy that regression‑tested 45 mice; the work, published in PNAS after Nature declined to publish, has not been tested in humans or metastases. The flashy public rollout and patent push by Barbacid’s Vega Oncotargets drew patient inquiries and criticism from CNIO colleagues for overclaiming and conflicts of interest. Independent experts urge cautious optimism, noting the (promising but early) preclinical results and emphasizing that mouse outcomes rarely translate to human cures, with human trials years away and more work needed on safety and efficacy.

via EL PAÍS English|

#barbacid #kras #pancreatic-cancer

health3 months ago•56 min saved

Three-drug combo eliminates pancreatic tumors in mice, signaling potential human therapies

A triple-drug regimen that targets three cancer-growth pathways—KRAS, its related pathway, and STAT3—completely eradicated pancreatic tumors across three mouse models, prevented tumor recurrence for about seven months, and showed no significant toxicity in mice. The treatment uses afatinib, daraxonrasib, and a novel STAT3 inhibitor. While the results are promising, researchers caution that mouse findings may not translate to humans and plan further drug development and clinical testing across diverse KRAS mutations.

via Live Science|

#health #kras #mice-model

science3 months ago•11 min saved

Triple KRAS Pathway Blockade Drives Complete Regression of Pancreatic Tumors in Preclinical Tests

Spanish researchers report a three-drug combo (RMC-6236/daraxonrasib, Afatinib, SD36) that simultaneously targets RAF1 (KRAS downstream), EGFR (upstream) and STAT3 signaling, producing complete regression of pancreatic tumors in orthotopic mouse models and patient-derived tissues with no resistance for more than 200 days, suggesting potential clinical trials for pancreatic ductal adenocarcinoma.

via Drug Target Review|

#kras #pancreatic-cancer #pdac

health3 months ago•3 min saved

Triple-therapy breakthrough halts pancreatic tumors in mice

Spanish CNIO researchers report that a triple combination therapy—an experimental KRAS inhibitor, an existing lung-cancer drug, and a protein degrader—caused long-lasting regression and prevented recurrence of pancreatic ductal adenocarcinoma in three mouse models, a potential path toward new clinical trials, though optimization for patients and trials is not yet planned.

via Euronews.com|

#cnio #health #kras

health9 months ago•3 min saved

Promising New Vaccine Targets Two Deadly Cancers in Clinical Trials

A new off-the-shelf vaccine called ELI-002 2P shows promising results in clinical trials for treating pancreatic and colorectal cancers by targeting KRAS gene mutations, with many patients developing strong immune responses and extended survival times, offering hope for more effective cancer therapies.

via yahoo.com|

#cancer #clinical-trial #health

health9 months ago•2 min saved

Advances in Cancer Vaccines and Early Detection Signs

An early study suggests that an off-the-shelf cancer vaccine targeting KRAS mutations may boost immune response and prolong survival in some pancreatic and bowel cancer patients, but larger studies are needed to confirm its effectiveness.

via Euronews.com|

#cancer #clinical-trial #health

health9 months ago•4 min saved

Innovative Molecule Simultaneously Targets Tumors and Silences Two 'Undruggable' Cancer Genes

UNC researchers have developed a novel 'two-in-one' molecule using inverted RNAi technology that can simultaneously silence two challenging cancer genes, KRAS and MYC, and deliver drugs to tumors, offering promising new treatment avenues for difficult cancers.

via Medical Xpress|

#cancer #health #kras

health1 year ago•3 min saved

Revolutionary Cancer Drug Enhances Radiation Therapy Effectiveness

UC San Francisco scientists have developed a targeted radiation therapy that combines a cancer drug with a radioactive antibody to selectively destroy cancer cells, minimizing damage to healthy tissue. This approach, which effectively eliminated lung and bladder tumors in mice, uses a drug to flag cancer cells and a radioactive antibody to deliver precise radiation, potentially overcoming tumor resistance. The team is working on adapting this method for broader patient use by developing antibodies that account for individual cellular differences.

via UC San Francisco|

#antibody #cancer #health

science-and-technology2 years ago•3 min saved

Unveiling New Strategies to Target and Inhibit KRAS in Cancer

Researchers have created multiple global atlases of inhibitory allosteric communication in KRAS, a protein involved in signaling pathways and a known therapeutic target. By quantifying the impact of over 26,000 mutations on the folding and binding of KRAS, the study identified allosteric sites that can be targeted for inhibition. The central beta sheet of KRAS was found to be particularly effective in allosteric propagation, and multiple surface pockets were validated as allosterically active, including a distal pocket in the C-terminal lobe of the protein. This research provides insights into the regulatory and therapeutic potential of allosteric modulation in proteins.

via Nature.com|

#allosteric-sites #biophysical-measurements #kras

pharmaceuticals2 years ago•0 min saved

Roche's KRAS Drug Shows Promising Results in NEJM Study

Roche has published Phase I data on its KRAS G12C inhibitor in the New England Journal of Medicine, showcasing its potential as a monotherapy across various cancers. The study included 137 patients with non-small cell lung cancer, colorectal cancer, and other solid tumors, as Roche aims to catch up with and surpass competitors Amgen and Mirati in the KRAS race.

via Endpoints News|

#cancer #clinical-trial #drug-development